Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neurology, PIP number: P/0298/2023

Opinion/decision on a Paediatric investigation plan (PIP): Wegovy, semaglutide, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0296/2023

Opinion/decision on a Paediatric investigation plan (PIP): Xeljanz, Tofacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0308/2023

EMEA-002381-PIP02-23

Opinion/decision on a Paediatric investigation plan (PIP): NexoBrid, Concentrate of proteolytic enzymes in bromelain, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Other, PIP number: P/0334/2023

Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Dermatology, PIP number: P/0297/2023

Opinion/decision on a Paediatric investigation plan (PIP): Opdivo, nivolumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0339/2023

Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0295/2023

Opinion/decision on a Paediatric investigation plan (PIP): Sivextro, tedizolid phosphate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0340/2023

Opinion/decision on a Paediatric investigation plan (PIP): Mysimba, bupropion hydrochloride,naltrexone hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0294/2023